Alaunos Therapeutics: receives Nasdaq delisting notice

What happened Alaunos Therapeutics reported that on Apr 9, 2026 it received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating the company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The company said it timely submitted a plan to regain compliance. On Oct 5, 2026 the company received a written notice from the Staff informing that its securities were subject to delisting unless the company timely requests a hearing before the Nasdaq Hearings Panel. The company plans to timely request a hearing, which will stay any further suspension or delisting action at least until the hearing and any extension granted by the Panel expires.

Key details

• Nasdaq Listing Rule cited: Nasdaq Listing Rule 5550(b)(1), $2,500,000 minimum stockholders’ equity requirement.
• Apr 9, 2026: initial noncompliance notice; Oct 5, 2026: written notice that securities are subject to delisting.
• The company is exploring strategic alternatives and is working with a financial advisor to complete one or more potential transactions to regain compliance.
• The filing states there can be no assurance the Panel will grant continued listing, that the company will evidence compliance within any extension, or that any potential transaction will be completed or achieve compliance.

Why it may matter This filing reports Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, which covers notices that a listed company’s securities are subject to suspension or delisting for failure to meet exchange listing requirements. A filing does not show why the insider traded or why the company acted.